Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2022-06-07 00:00:00 ET · period of report 2022-06-03 · accession 0001104659-22-069015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-07 | 2022-06-03 | APRE | SCHADE CHRISTIAN S | COB, CEO, Dir | F - Tax | $0.81 | -65.8K | 226.8K | -22% | -$53.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-03 | F | D | 65,770 | $0.81 | 226,846 | D | — | — | (F1) Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 180,934 restricted stock units. |